The KRAS polymorphisms have been reported to influence the sensitivity and prognosis of various cancers of anti-targeted drug therapy, including lung cancer [24], gastric cancer [25], triple-negative breast cancer [26]. This evidence concerns the gene KRAS and gastric cancer.